Cover Image

Characterization of Plant-Derived Natural Inhibitors of Dipeptidyl Peptidase-4 as Potential Antidiabetic Agents: A Computational Study

Diabetes, characterized by elevated blood sugar levels, poses significant health and economic risks, correlating with complications like cardiovascular disease, kidney failure, and blindness. Dipeptidyl peptidase-4 (DPP-4), also referred to as T-cell activation antigen CD26 (EC 3.4.14.5.), plays a c...

Full description

Saved in:

Bibliographic Details
Main Authors:	Alomgir Hossain (Author), Md Ekhtiar Rahman (Author), Md Omar Faruqe (Author), Ahmed Saif (Author), Suzzada Suhi (Author), Rashed Zaman (Author), Abdurahman Hajinur Hirad (Author), Mohammad Nurul Matin (Author), Muhammad Fazle Rabbee (Author), Kwang-Hyun Baek (Author)
Format:	Book
Published:	MDPI AG, 2024-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
by: Chenkai Cui, et al.
Published: (2022)

Molecular Docking of Compounds in Moringa oleifera Lam with Dipeptidyl Peptidase-4 Receptors as Antidiabetic Candidates
by: Indah Permata Rendi, et al.
Published: (2021)

Navigating the chemical space of dipeptidyl peptidase-4 inhibitors
by: Shoombuatong W, et al.
Published: (2015)

Dipeptidyl Peptidase IV Inhibitory Activity of Berberine and Mangiferin: An In Silico Approach
by: Ipseeta Ray Mohanty, et al.
Published: (2017)

Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid,
by: Agoritsa Gravani, et al.
Published: (2022)

Pharmacological and Clinical Studies of Medicinal Plants That Inhibit Dipeptidyl Peptidase-IV
by: Rohani, et al.
Published: (2023)

UNEXPECTED ADVERSE REACTIONS OF THE DRUGS OF THE GROUP OF INHIBITORS OF DIPEPTIDYL PEPTIDASE-4
by: T. V. Romanova, et al.
Published: (2018)

The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: from to
by: Shian-Ren Lin, et al.
Published: (2019)

Pemphigoid nodularis induced by long-term use of dipeptidyl peptidase-4 inhibitors
by: Natsumi Norikawa, et al.
Published: (2023)

Dipeptidyl Peptidase-4 Inhibitor-associated Bullous Pemphigoid: Recurrence with Epitope Spreading
by: Hiroyuki Takama, et al.
Published: (2018)

Novel Dipeptidyl Peptidase-4-Inhibiting Peptide Derived From β-Lactoglobulin
by: Masayuki Uchida, et al.
Published: (2011)

Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Metabolism and the Possible Underlying Mechanisms
by: Yinqiu Yang, et al.
Published: (2017)

Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors
by: Jong-Mi Seong, et al.
Published: (2021)

Serum dipeptidyl peptidase-4 activity and progranulin level in polycystic ovary syndrome
by: Maryam Abolghasemi, et al.
Published: (2022)

Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl‐peptidase IV inhibitors (DPP4i): Can polypharmacology help explain?
by: Lauren Jones, et al.
Published: (2022)

The effects of dipeptidyl peptidase-4 on cardiac fibrosis in pressure overload-induced heart failure
by: Masanori Hirose, et al.
Published: (2017)

Novel N-substituted aminobenzamide scaffold derivatives targeting the dipeptidyl peptidase-IV enzyme
by: Al-Balas QA, et al.
Published: (2014)

Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer's disease: a narrative review
by: Xin Jiang, et al.
Published: (2024)

Effects of Combination Treatment With Dipeptidyl Peptidase IV Inhibitor and Sulfonylurea on Glucose Levels in Rats
by: Kotaro Takasaki, et al.
Published: (2004)

Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus
by: Yayoi Nishida, et al.
Published: (2020)

Dipeptidyl peptidase 4 expression is not associated with an activated fibroblast phenotype in idiopathic pulmonary fibrosis
by: Måns Kadefors, et al.
Published: (2022)

Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
by: Hiroki Esaki, et al.
Published: (2017)

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
by: Capuano A, et al.
Published: (2013)

CD26/dipeptidyl peptidase IV contributes to tumor metastasis in human lung adenocarcinoma
by: Lei Liu, et al.
Published: (2013)

Rurality is associated with lower likelihood of dipeptidyl peptidase 4 inhibitor use for treatment intensification
by: Danielle K. Nagy, et al.
Published: (2024)

Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors
by: Rahim K, et al.
Published: (2024)

Hepatoprotective effect of dipeptidyl peptidase-4 inhibitor sitagliptin against carbon tetrachloride-induced liver fibrosis in mice
by: Ahmed A.N Ahmed, et al.
Published: (2021)

Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid
by: Outi Lindgren, et al.
Published: (2019)

Dipeptidyl peptidase IV inhibitors and the risk of mycobacterial pulmonary infections in type 2 diabetes mellitus
by: Cheng-Yi Wang, et al.
Published: (2023)

Macrocarpal C isolated from Eucalyptus globulus inhibits dipeptidyl peptidase 4 in an aggregated form
by: Eisuke Kato, et al.
Published: (2018)

An ethnopharmacology study of Indonesian medicinal plants in Gunung Sari village as dipeptidyl peptidase-IV inhibitor
by: Greesty Finotory Swandiny, et al.
Published: (2023)

Soluble Dipeptidyl Peptidase-4 Induces Fibroblast Activation Through Proteinase-Activated Receptor-2
by: Shih-Yi Lee, et al.
Published: (2020)

Significance of Vascular Dipeptidyl Peptidase-4 Inhibition on Vascular Protection in Zucker Diabetic Fatty Rats
by: Shinji Takai, et al.
Published: (2014)

Design, synthesis and anti-diabetic activity of piperazine sulphonamide derivatives as dipeptidyl peptidase-4 inhibitors
by: Swarna Bharathi Kalli, et al.
Published: (2022)

Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital
by: Woh Yon Mak, et al.
Published: (2020)

A Comprehensive Review and Perspective on Natural Sources as Dipeptidyl Peptidase-4 Inhibitors for Management of Diabetes
by: Sibhghatulla Shaikh, et al.
Published: (2021)

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Atherosclerosis, β-Cell Function, and Glycemic Control in Japanese Patients with Type 2 Diabetes Mellitus Who are Treatment Naïve or Poorly Responsive to Antidiabetes Agents: A Multicenter, Prospective Observational, Uncontrolled Study
by: Yuya Tsurutani, MD, PhD, et al.
Published: (2017)

Serum autoantibodies against the extracellular region of α6β4 integrin in a patient with dipeptidyl peptidase-4 inhibitor-induced bullous pemphigoid
by: Chigusa Yamashita, MD, et al.
Published: (2022)

Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients
by: Kamran Balighi, et al.
Published: (2022)

Dipeptidyl peptidase III as a DNA marker to investigate epidemiology and taxonomy of Old World Leishmania species.
by: Insaf Bel Hadj Ali, et al.
Published: (2021)